Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bind Biosciences will work with Amgen to develop kinase inhibitor nanomedicines to treat a range of solid tumors. Cambridge, Mass.-based Bind says it could receive up-front and development milestone payments totaling $46.5 million and up to $134 million more for regulatory and sales milestones. Bind is developing targeted and programmable therapeutics it calls Accurins. The partners are looking to develop a new Accurin around a proprietary kinase inhibitor from Amgen.
This article has been sent to the following recipient: